{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:21Z","timestamp":1788262161629,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41375-019-0563-0","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T18:10:01Z","timestamp":1567447801000},"page":"488-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy"],"prefix":"10.1038","volume":"34","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-2621","authenticated-orcid":false,"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"563_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"563_CR4","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36:231\u20137.","journal-title":"J Clin Oncol."},{"key":"563_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14:141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1200\/JCO.2017.75.4663","volume":"36","author":"NP Shah","year":"2018","unstructured":"Shah NP. Front-line treatment options for chronic-phase chronic myeloid leukemia. J Clin Oncol. 2018;36:220\u20134.","journal-title":"J Clin Oncol"},{"key":"563_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2016;2016:170\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"563_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"563_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014;23:825\u201336.","journal-title":"Qual Life Res"},{"key":"563_CR13","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001."},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"P Rosenbaum","year":"1983","unstructured":"Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"563_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33\u20138.","journal-title":"Am Stat"},{"key":"563_CR16","doi-asserted-by":"crossref","unstructured":"Pooler JA, Srinivasan M. Association between supplemental nutrition assistance program participation and cost-related medication nonadherence among older adults with diabetes. JAMA Intern Med. 2019;179:63\u201370.","DOI":"10.1001\/jamainternmed.2018.5011"},{"key":"563_CR17","doi-asserted-by":"crossref","unstructured":"Kwon IG, Son T, Kim HI, Hyung WJ. Fluorescent lymphography-guided lymphadenectomy during robotic radical gastrectomy for gastric cancer. JAMA Surg. 2019;154:150\u20138.","DOI":"10.1001\/jamasurg.2018.4267"},{"key":"563_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0338-0","volume":"17","author":"TL Nguyen","year":"2017","unstructured":"Nguyen TL, Collins GS, Spence J, Daures JP, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Method. 2017;17:78.","journal-title":"BMC Med Res Method"},{"key":"563_CR19","doi-asserted-by":"crossref","unstructured":"Cottone F, Anota A, Bonnetain F, Collins GS, Efficace F. Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes. Pharmacoepidemiol Drug Saf. 2019;28:690\u20139.","DOI":"10.1002\/pds.4756"},{"key":"563_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2307\/2981697","volume":"147","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR. The consquences of adjustment for a concomitant variable that has been affected by the treatment. J R Stat Soc Ser A. 1984;147:656\u201366.","journal-title":"J R Stat Soc Ser A"},{"key":"563_CR21","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554\u201360.","journal-title":"Blood"},{"key":"563_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","volume":"83","author":"AT Johnsen","year":"2009","unstructured":"Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83:139\u201348.","journal-title":"Eur J Haematol"},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1\u201328.","journal-title":"J Stat Softw"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119:1123\u20139.","journal-title":"Blood"},{"key":"563_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097\u2013103.","journal-title":"Support Care Cancer"},{"key":"563_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27:1511\u20139.","journal-title":"Leukemia"},{"key":"563_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16:1108\u201335.","journal-title":"J Natl Compr Cancer Netw"},{"key":"563_CR28","doi-asserted-by":"crossref","unstructured":"Kluetz PG, O\u2019Connor DJ, Soltys K.\u00a0Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol. 2018;19:e267\u201374.","DOI":"10.1016\/S1470-2045(18)30097-4"},{"key":"563_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"563_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003;21:2138\u201346.","journal-title":"J Clin Oncol"},{"key":"563_CR31","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood.V126.23.4024.4024","volume":"126","author":"AM Labeit","year":"2015","unstructured":"Labeit AM, Copland M, Cork LM, Hedgley CA, Foroni L, Osborne WL, et al. Assessment of quality of life in the NCRI spirit 2 study comparing imatinib with dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Blood. 2015;126:4024.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0563-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T21:36:50Z","timestamp":1721684210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0563-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FE: <i>Consultancy<\/i>: BMS, Amgen, Orsenix, Incyte\u00a0and Takeda. MBr: <i>Honoraria<\/i>: Novartis, BMS, Pfizer, Incyte, Celgene. MBo: <i>Research funding<\/i>: Novartis; <i>Consultancy<\/i>: Bristol Myers Squibb. FCa: <i>Consultancy:<\/i> Novartis, Bristol Myers Squibb, Pfizer, Incyte; <i>Honoraria<\/i>: Novartis, Bristol Myers Squibb, Pfizer, Incyte. MC: <i>Honoraria:<\/i> Incyte, Novartis, Celgene, Amgen. AP: <i>Research funding:<\/i> Novartis. SS: <i>Research funding:<\/i> Novartis, Bristol Myers Squibb, Incyte; <i>Honoraria<\/i>: Novartis, Bristol Myers Squibb, Incyte, Pfizer. GB: <i>Honoraria:<\/i> Incyte, Pfizer, Bristol Myers Squibb, Novartis. GR: <i>Honoraria:<\/i> Novartis, Bristol Myers Squibb, Pfizer, Incyte. MV: <i>Consultancy<\/i> and <i>Advisory board<\/i>: Jazz Healthcare, Millennium Pharmaceuticals. <i>Educational meeting<\/i>: Pfizer","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}